Results 41 to 50 of about 46,872 (214)
Renoprotective Effects of SGLT2 Inhibitors
Heart Failure Clinics, 2022 SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
openaire +4 more sources
SGLT2 Inhibitor–Induced Sympathoinhibition
JACC: Basic to Translational Science, 2020 Summary: Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression.
Lakshini Y. Herat, PhD +10 more
openaire +2 more sources
Asian Journal of Pharmaceutical Research and Development, 2023 The pharmaceutical industry employs a variety of analytical techniques to test the quality, concentration, and composition of medicines in biological fluids. This review work to provide the most existing analytical methods for the analysis of SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) in active pharmaceutical ingredients, biological
Pravin Dighe, Namrata Kale
openaire +1 more source
Scientific Reports, 2017 Carbasugar sodium-glucose cotransporter 2 (SGLT2) inhibitors are highly promising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM). However, the clinical usage of carbasugar SGLT2 inhibitors has been underexplored, due to the lengthy ...
Wai-Lung Ng +5 more
doaj +1 more source
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial [PDF]
, 2018 Aims/hypothesis: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 ...
Fitchett, David +4 more
core +1 more source
Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns [PDF]
Exploration of MedicineSodium-glucose cotransporter 2 (SGLT2) inhibitors are integral to diabetes treatment, facilitating renal glucose excretion and offering benefits in cardiovascular risk reduction, kidney function preservation, and weight management.
Farazul Hoda +8 more
doaj +1 more source
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels [PDF]
, 2019 学位記番号 ...
Suga, Takayoshi +2 more
core
Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease [PDF]
, 2017 BACKGROUND: The sodium–glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes.
Cain, V +5 more
core +1 more source
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS [PDF]
Archiv EuromedicaDue to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels.
Karol Wielgus +9 more
openaire +1 more source
SGLT2 Inhibitors for Nephrologists
EMJ Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides. Sodium-glucose co-transporter-2 inhibitors are a relatively new class of oral antidiabetic drugs.
Mufti Baleegh-ur-Raheem Mahmood +1 more
openaire +2 more sources